Mednext Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 5.05 M
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.82 Cr
- Satisfied Charges ₹ 1.10 Cr
- Revenue Growth -3.71%
- Profit Growth 37.97%
- Ebitda 118.22%
- Net Worth 1.26%
- Total Assets 57.79%
About Mednext Pharma
Mednext Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 February 2009 and has a history of 15 years and 11 months. Its registered office is in Navi Mumbai, Maharashtra.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 5.05 M.
The company currently has active open charges totaling ₹19.82 Cr. The company has closed loans amounting to ₹1.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Vyas and Neelam Vyas serve as directors at the Company.
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24110MH2009PTC190076
- Company No.
190076
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Mednext Pharma Private Limited offer?
Mednext Pharma Private Limited offers a wide range of products and services, including Antihistamines, Loratadine, Skin Care Cosmetics, Sun Protection Cream, Injectable Products, Pharmaceutical Injectables, Allopathic Cough Syrup, Anti Cold Syrup, Body Cream, Anti Acne Cream.
Who are the key members and board of directors at Mednext Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Vyas  | Director | 03-Feb-2009 | Current |
| Neelam Vyas | Director | 04-Mar-2017 | Current |
Financial Performance of Mednext Pharma.
Mednext Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.71% decrease. The company also saw a substantial improvement in profitability, with a 37.97% increase in profit. The company's net worth moved up by a moderate rise of 1.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mednext Pharma?
In 2023, Mednext Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mednext Biotech LimitedAnil Vyas and Neelam Vyas are mutual person
Alice Pharma Private LimitedAnil Vyas and Neelam Vyas are mutual person
- Alice Pharma (Mumbai) Private Limited
Neelam Vyas is a mutual person
Ceza Formulations Private LimitedAnil Vyas is a mutual person
- Tirtham Hospitality Private Limited
Anil Vyas and Neelam Vyas are mutual person
Charges (Loans)
₹19.82 Cr
₹1.10 Cr
Charges Breakdown by Lending Institutions
- Others : 16.59 Cr
- Axis Bank Limited : 2.23 Cr
- Indusland Bank Limited : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Mar 2022 | Others | ₹16.59 Cr | Open |
| 19 Feb 2016 | Axis Bank Limited | ₹2.23 Cr | Open |
| 16 Jan 2015 | Indusland Bank Limited | ₹1.00 Cr | Open |
| 21 Oct 2013 | Canara Bank | ₹1.10 Cr | Satisfied |
How Many Employees Work at Mednext Pharma?
Unlock and access historical data on people associated with Mednext Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mednext Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mednext Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
